Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2013
No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yousef Yacoub A, Halliday William, Chan Helen S L, Héon Elise, Gallie Brenda L, Dimaras Helen
Аннотация
OBJECTIVE: To report our long-term experience with the local toxicity profile and ocular motility changes after treatment of intraocular retinoblastoma with subtenon topotecan chemotherapy.
DESIGN: Cross-sectional study.
PARTICIPANTS: Ten eyes in 8 patients with retinoblastoma treated with subtenon topotecan.
METHODS: We assessed potential complications in ocular motility in eyes with retinoblastoma treated with subtenon topotecan using forced duction testing under general anaesthesia. Eyes subsequently enucleated because of treatment failure were examined histologically.
RESULTS: Ten eyes in 8 patients with retinoblastoma treated with 1 to 4 injections of subtenon topotecan were examined repeatedly, with a mean follow-up period of 37 months. Ocular motility remained normal in all eyes by forced duction, with no observed persistent conjunctival congestion, abnormal ocular motility, or enophthalmos in retained eyes 3 years after last injection. Histopathologic examination of the 2 enucleated eyes did not reveal signs of orbital tissue necrosis or fibrosis.
CONCLUSIONS: Unlike subtenon carboplatin, subtenon topotecan therapy is not associated with long-term toxicity affecting ocular muscles or orbital soft tissue. No effect on ocular motility was observed.
DESIGN: Cross-sectional study.
PARTICIPANTS: Ten eyes in 8 patients with retinoblastoma treated with subtenon topotecan.
METHODS: We assessed potential complications in ocular motility in eyes with retinoblastoma treated with subtenon topotecan using forced duction testing under general anaesthesia. Eyes subsequently enucleated because of treatment failure were examined histologically.
RESULTS: Ten eyes in 8 patients with retinoblastoma treated with 1 to 4 injections of subtenon topotecan were examined repeatedly, with a mean follow-up period of 37 months. Ocular motility remained normal in all eyes by forced duction, with no observed persistent conjunctival congestion, abnormal ocular motility, or enophthalmos in retained eyes 3 years after last injection. Histopathologic examination of the 2 enucleated eyes did not reveal signs of orbital tissue necrosis or fibrosis.
CONCLUSIONS: Unlike subtenon carboplatin, subtenon topotecan therapy is not associated with long-term toxicity affecting ocular muscles or orbital soft tissue. No effect on ocular motility was observed.
Предметные рубрики MeSH
Child, PreschoolCombined Modality TherapyCross-Sectional StudiesEye EnucleationEye Movement MeasurementsEye MovementsFibrin Tissue AdhesiveFollow-Up StudiesHumansInfantInfant, NewbornInjectionsOcular Motility DisordersPostoperative ComplicationsRetinal NeoplasmsRetinoblastomaRetrospective StudiesTenon CapsuleTissue AdhesivesTopoisomerase I InhibitorsTopotecanTreatment Failure